+ Phase-III-support-Carcinogenicity

Carcinogenicity

We have long-held experience of conducting carcinogenicity studies in the pharmaceutical and chemical industry sectors; having undertaken them for more than 30 years.  Studies are run in our purpose built rodent facilities where technologists have well-honed skills in dosing over prolonged periods and in palpation of masses.

Pathology is critical for the successful outcome of these studies and we employ three full-time toxicological pathologists with combined experience amounting to over six decades, including extensive carcinogenicity study experience. The qualifications of our pathologists are detailed below:

  • Pathologist A: BDS(Edin) DipRCPath (Tox) FRCPath
  • Pathologist B: BSc PhD DipRCPath (Tox) FRCPath
  • Pathologist C: DVM MRCVS

Statistical analysis is overseen by one of the leading UK experts in this field.

Study Types

  • 2 year “lifetime” bioassays
  • Preliminary 3 month toxicity studies
  • rasH2 transgenic mouse model

Dose Routes

  • Dietary
  • Oral gavage
  • Sub-cutaneous
Our News & Events
Biomarker Validation – Mountain, Molehill or Something in Between?
13 June 2018
Biomarker Validation – Mountain, Molehill or Something in Between?
Read More
More sex, more strain and we are all a bit older…
19 April 2018
Immunophenotyping of lymphocyte subsets
Read More
Moving to Minipigs?
29 March 2018
Moving to Minipigs?
Read More